GlycoEra AG

GlycoEra AG

Biotechnologieforschung

Wädenswil, Zurich 3.089 Follower:innen

Advancing Glycan Mediated Therapy

Info

GlycoEra is positioned as the leading precision protein degradation company. Bifunctional biologics (G-LyTACs), designed by our novel and proprietary technology bind to disease-causing proteins and transport them to the lysosome using naturally occurring endocytic receptors. The disease-causing proteins are degraded in the lysosome and removed from the body. Unlike intracellular protein degraders, like PROTACs and molecular glues, our technology can access targets that are extracellular and membrane proteins, thereby opening up novel targets and therapeutic areas for intervention.

Branche
Biotechnologieforschung
Größe
11–50 Beschäftigte
Hauptsitz
Wädenswil, Zurich
Art
Privatunternehmen
Gegründet
2020
Spezialgebiete
Glycoengineering, Therapeutic product development und Biopharmaceutical CMC development

Orte

Beschäftigte von GlycoEra AG

Updates

Ähnliche Seiten

Finanzierung